Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

A pharmacogenetic intervention for the improvement of the safety profile of antipsychotic treatments
María J. Arranz, Alex Gonzalez-Rodriguez, Josefina Pérez‐Blanco, et al.
Translational Psychiatry (2019) Vol. 9, Iss. 1
Open Access | Times Cited: 40

Showing 1-25 of 40 citing articles:

Antipsychotic Polypharmacy for the Management of Schizophrenia: Evidence and Recommendations
Markku Lähteenvuo, Jari Tiihonen
Drugs (2021) Vol. 81, Iss. 11, pp. 1273-1284
Open Access | Times Cited: 96
A review of real-world evidence on preemptive pharmacogenomic testing for preventing adverse drug reactions: a reality for future health care
Santenna Chenchula, Shubham Atal, Chakradhara Rao S. Uppugunduri
The Pharmacogenomics Journal (2024) Vol. 24, Iss. 2
Open Access | Times Cited: 16
Optimisation of pharmacotherapy in psychiatry through therapeutic drug monitoring, molecular brain imaging and pharmacogenetic tests: Focus on antipsychotics
X.M. Hart, Gerhard Gründer, Nicolas Ansermot, et al.
The World Journal of Biological Psychiatry (2024) Vol. 25, Iss. 9, pp. 451-536
Closed Access | Times Cited: 9
A systematic review of pharmacogenetic testing to guide antipsychotic treatment
Noushin Saadullah Khani, Georgie Hudson, Georgina Mills, et al.
Nature Mental Health (2024) Vol. 2, Iss. 5, pp. 616-626
Open Access | Times Cited: 6
Pharmacogenetics of antipsychotics: Clinical utility and implementation
María J. Arranz, Juliana Salazar, Marta Hernández
Behavioural Brain Research (2020) Vol. 401, pp. 113058-113058
Closed Access | Times Cited: 31
Metabolizing status of CYP2C19 in response and side effects to medications for depression: Results from a naturalistic study
Marco Calabrò, Chiara Fabbri, Siegfried Kasper, et al.
European Neuropsychopharmacology (2022) Vol. 56, pp. 100-111
Closed Access | Times Cited: 14
Antipsychotic Polypharmacy-Related Cardiovascular Morbidity and Mortality: A Comprehensive Review
Amber N. Edinoff, Emily D. Ellis, Laura M. Nussdorf, et al.
Neurology International (2022) Vol. 14, Iss. 1, pp. 294-309
Open Access | Times Cited: 14
Utility of pharmacogenetic testing to optimise antidepressant pharmacotherapy in youth: a narrative literature review
Bradley Roberts, Zahra Cooper, Stephanie Lu, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 8
Acceptability of Pharmacogenetic Testing among French Psychiatrists, a National Survey
Benjamin Laplace, Benjamin Calvet, Aurélie Lacroix, et al.
Journal of Personalized Medicine (2021) Vol. 11, Iss. 6, pp. 446-446
Open Access | Times Cited: 18
The Influence of CYP2D6 and CYP2C19 Genetic Variation on Diabetes Mellitus Risk in People Taking Antidepressants and Antipsychotics
Isabelle Austin-Zimmerman, Marta Wrońska, Baihan Wang, et al.
Genes (2021) Vol. 12, Iss. 11, pp. 1758-1758
Open Access | Times Cited: 16
CYP2D6 Genetic Variation and Antipsychotic-Induced Weight Gain: A Systematic Review and Meta-Analysis
Yanisa Wannasuphoprasit, Stig Ejdrup Andersen, María J. Arranz, et al.
Frontiers in Psychology (2022) Vol. 12
Open Access | Times Cited: 11
Pharmacogenetic Interventions Improve the Clinical Outcome of Treatment-Resistant Autistic Spectrum Disorder Sufferers
María J. Arranz, Juliana Salazar, Valentín Bote, et al.
Pharmaceutics (2022) Vol. 14, Iss. 5, pp. 999-999
Open Access | Times Cited: 11
Pharmacogenomics to support mental health medication therapy management: Clinical practice considerations and a conceptual framework to enhance patient care
Jeffrey R. Bishop, Mark E. Schneiderhan, Tiana Butler, et al.
JACCP JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY (2023) Vol. 7, Iss. 2, pp. 160-170
Open Access | Times Cited: 6
CYP2D6 Phenotype Influences Aripiprazole Tolerability in Pediatric Patients with Mood Disorders
Sahar A. Jallaq, Mark Verba, Jeffrey R. Strawn, et al.
Journal of Child and Adolescent Psychopharmacology (2020) Vol. 31, Iss. 1, pp. 56-62
Open Access | Times Cited: 13
Divergent Phenotypes, Actionable Genotypes, and Phenoconversion in a German Psychiatric Inpatient Population: Results from the FACT-PGx Study
Andreas Eckert, Amelie Frantz, Maike Scherf‐Clavel, et al.
Journal of Exploratory Research in Pharmacology (2024) Vol. 9, Iss. 2, pp. 79-85
Open Access | Times Cited: 1
Pharmacogenomics-assisted schizophrenia management: A hybrid type 2 effectiveness-implementation study protocol to compare the clinical utility, cost-effectiveness, and barriers
Aniruddha Basu, Atanu Kumar Dutta, Bhavani Shankara Bagepally, et al.
PLoS ONE (2024) Vol. 19, Iss. 4, pp. e0300511-e0300511
Open Access | Times Cited: 1
Pharmacogenetic intervention improves treatment outcomes in Chinese adult men with schizophrenia
Ying Qin, Yanjing Liu, Jingwen Zhao, et al.
Journal of Psychiatric Research (2024) Vol. 174, pp. 129-136
Closed Access | Times Cited: 1
Pharmacogenomics-assisted treatment versus standard of care in schizophrenia: a systematic review and meta-analysis
Saibal Das, Manoj Kalita, Manabendra Makhal, et al.
BMC Psychiatry (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 1
Antipsychotic Polypharmacy
Adriana Foster, Jordanne King
FOCUS The Journal of Lifelong Learning in Psychiatry (2020) Vol. 18, Iss. 4, pp. 375-385
Open Access | Times Cited: 10
Moderators and mediators of antipsychotic response in delusional disorder: Further steps are needed
Alexandre González-Rodríguez, Armand Guàrdia, Diego Palao, et al.
World Journal of Psychiatry (2020) Vol. 10, Iss. 4, pp. 34-45
Open Access | Times Cited: 9
Collaboration between Psychiatrists and Other Allied Medical Specialists for the Treatment of Delusional Disorders
Alexandre González-Rodríguez, José Antonio Monreal, M. Natividad, et al.
Healthcare (2022) Vol. 10, Iss. 9, pp. 1729-1729
Open Access | Times Cited: 5
Pharmacogenomic Studies in Intellectual Disabilities and Autism Spectrum Disorder: A Systematic Review
Kazunari Yoshida, Emiko Koyama, Clement C. Zai, et al.
The Canadian Journal of Psychiatry (2020) Vol. 66, Iss. 12, pp. 1019-1041
Open Access | Times Cited: 6
Pharmacogenomics in Psychiatric Diseases
Adrijana Kekic
Springer eBooks (2023), pp. 147-185
Closed Access | Times Cited: 2
Alcohol intake potentiates clozapine adverse effects associated to CYP1A2*1C in patients with refractory psychosis
Alberto Ortega‐Vázquez, Yerye Gibrán Mayén-Lobo, David José Dávila‐Ortiz de Montellano, et al.
Drug Development Research (2020) Vol. 82, Iss. 5, pp. 685-694
Closed Access | Times Cited: 5
The influence of CYP2D6 and CYP2C19 genetic variation on diabetes mellitus risk in people taking antidepressants and antipsychotics
Isabelle Austin-Zimmerman, Marta Wrońska, Baihan Wang, et al.
medRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 5
Page 1 - Next Page

Scroll to top